Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease by Brusse-Keizer, Marjolein et al.
© 2015 Brusse-Keizer et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of COPD 2015:10 455–461
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
455
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S70355
Amoxicillin concentrations in relation to beta-
lactamase activity in sputum during exacerbations 
of chronic obstructive pulmonary disease
Marjolein Brusse-Keizer1
Paul VanderValk2
Rogier W van der Zanden3
Lars Nijdam4
Job van der Palen1,5
Ron Hendrix6,7
Kris Movig4
1Medical School Twente, 2Department 
of Pulmonary Medicine, Medisch 
Spectrum Twente, Enschede, 
3Department of Clinical Pharmacy 
and Toxicology, Maastricht 
University Medical Centre, 
Maastricht, 4Department of Clinical 
Pharmacy, Medisch Spectrum 
Twente, 5Department of Research 
Methodology, Measurement and 
Data Analysis, University of Twente, 
6Regional Laboratory of Public Health, 
Enschede, 7Department of Medical 
Microbiology, University Medical 
Centre Groningen, and University  
of Groningen, Groningen,  
the Netherlands
Correspondence: Marjolein Brusse-
Keizer 
Medisch Spectrum Twente, Medical 
School Twente, Haaksbergerstraat 55, 
7513 ER Enschede, the Netherlands 
Tel +315 3487 2000 
Email m.brusse-keizer@mst.nl
Background: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are often 
treated with antibiotics. Theoretically, to be maximally effective, the antibiotic concentration at 
sites of infection should exceed the minimum inhibitory concentration at which 90% of the growth 
of potential pathogens is inhibited (MIC
90
). A previous study showed that most hospitalized 
COPD patients had sputum amoxicillin concentrations ,MIC
90
 when treated with amoxicillin/
clavulanic acid. Those with adequate sputum concentrations had better clinical  outcomes. Low 
amoxicillin concentrations can be caused by beta-lactamase activity in the lungs. This study 
investigated whether patients with sputum amoxicillin concentrations ,MIC
90
 had higher beta-
lactamase activity in sputum than patients with a concentration $MIC
90
.
Methods: In total, 23 patients hospitalized for acute exacerbations of COPD and treated with 
amoxicillin/clavulanic acid were included. Sputum and serum samples were collected at day 3 
of treatment to determine beta-lactamase activity in sputum and amoxicillin concentrations in 
both sputum and serum.
Results: We found no difference in beta-lactamase activity between patients with sputum 
amoxicillin concentrations ,MIC
90
 and $MIC
90
 (P=0.79). Multivariate logistic regression 
analysis showed no significant relationship between beta-lactamase activity and sputum amoxi-
cillin concentrations ,MIC
90
 or $MIC
90
 (odds ratio 0.53; 95% confidence interval 0.23–1.2; 
P=0.13). Amoxicillin concentrations were ,MIC
90
 in 78% of sputum samples and in 30% of 
serum samples.
Conclusion: In patients treated with amoxicillin/clavulanic acid for an acute exacerbation 
of COPD, sputum beta-lactamase activity did not differ between those with sputum amoxicil-
lin concentrations ,MIC
90
 or $MIC
90
. The finding that the majority of patients had sputum 
amoxicillin concentrations ,MIC
90
 suggests that current treatment with antibiotics for acute 
exacerbations of COPD should be optimized.
Keywords: chronic obstructive pulmonary disease, exacerbation, amoxicillin, clavulanic acid, 
MIC
90
, concentration
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbid-
ity and mortality throughout the world. The prevalence and burden of COPD are 
projected to increase in the coming decades due to continued exposure to COPD risk 
factors and the changing age structure of the world’s population, with COPD likely 
to become the third leading cause of death by 2020.1 Morbidity and mortality among 
patients with COPD are in large part related to acute exacerbations (AECOPD), 
which impair respiratory, physical, social, and emotional functioning both acutely 
and longitudinally.2–4
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
456
Brusse-Keizer et al
The management of AECOPD is empirical and includes 
oral corticosteroids, often combined with antibiotics, 
although the need to prescribe these antibiotics is still 
not convincingly demonstrated.5 Most placebo-controlled 
antibiotics trials that have been performed have important 
limitations and are difficult to compare because different 
definitions of COPD and AECOPD and different endpoints 
have been used.6,7 Further, these trials were conducted several 
decades ago, before systemic steroids were widely introduced 
for the treatment of AECOPD.8–11 In a more recent placebo-
controlled study by Llor et al, treatment with amoxicillin/
clavulanic acid did show a beneficial effect; however, only 
17% of these patients received systemic steroids.12 In a study 
by Daniels et al, in which the add-on effect of antibiotics 
was investigated, no difference in clinical outcome after 30 
days was observed.13
Theoretically, to be maximally effective, the antibiotic 
concentration at sites of infection should exceed the mini-
mum inhibitory concentration at which 90% (MIC
90
) of the 
growth of potential COPD pathogens such as Haemophilus 
influenzae, Streptococcus pneumoniae, and Moraxella 
catarrhalis is inhibited. Levels of antimicrobial agents in 
sputum, where as a representation of the site of infection 
many potential pathogenic microorganisms are located, 
may be a more relevant predictor of efficacy of antibiotics in 
treatment of an AECOPD than concentrations in serum.14–16 
An antibiotic widely used in the treatment of AECOPD is 
amoxicillin/clavulanic acid.
In a former study by Brusse-Keizer et al, in which 33 
COPD patients were treated with amoxicillin/clavulanic 
acid for AECOPD, sputum amoxicillin concentrations 
proved to be an important determinant of clinical outcome. 
Patients with sputum amoxicillin concentrations ,MIC
90
 
were hospitalized for 4 days longer than patients with an 
amoxicillin concentration in sputum $MIC
90
 (7 versus 
11 days).  Moreover, 67% of patients in this study had a 
sputum amoxicillin concentration ,MIC
90
.17
The sputum amoxicillin concentration may differ mark-
edly from the concentrations in serum due to various factors, 
such as the diffusion of amoxicillin into the airways,18 which 
could be both a host-related as well as a drug-related factor.
A well-known drug-related factor associated with amoxi-
cillin is the susceptibility of amoxicillin to breakdown by 
beta-lactamase enzymes. In COPD, there are several potential 
pathogens (eg, H. influenza and M. catarrhalis) that produce 
these beta-lactamase enzymes.19 The use of beta-lactamase 
inhibitors, such as clavulanic acid, allows inactivation of cer-
tain beta-lactamases.20 An excessive beta-lactamase  activity 
in sputum of COPD patients compared with the dosage of 
clavulanic acid could possibly be an explanation for the 
earlier observed low numbers of COPD patients in which an 
amoxicillin concentration above the MIC
90
 was reached.
We therefore conducted a study to investigate whether 
there was any difference in beta-lactamase activity between 
COPD patients with a sputum amoxicillin concentration 
,MIC
90
 and those with a concentration $MIC
90
.
Materials and methods
Patients
This study was part of the Cohort of Mortality and Inflam-
mation in COPD (COMIC) study, a single-center prospective 
cohort study on the immune status of COPD patients as a 
determinant of survival. From December 2005 until April 
2010, 795 patients were included in the cohort, with a follow-
up period of 3 years. To be eligible for the cohort, patients had 
to meet the following criteria: a clinical diagnosis of COPD, as 
defined by the Global Initiative for Chronic Obstructive Lung 
Disease criteria;21 current or former smoker; age 40 years or 
over; no medical condition compromising survival within the 
follow-up period or serious psychiatric morbidity; absence of 
any other active lung disease (eg, sarcoïdosis); no maintenance 
therapy with antibiotics; and ability to speak Dutch.
In this exploratory study, we had no data available on which 
we could base our power calculations. We therefore included all 
patients from the COMIC study when they were hospitalized 
for an AECOPD that was treated with amoxicillin/clavulanic 
acid between November 2009 and March 2010.
An AECOPD was defined as an acute event characterized 
by a worsening of the patient’s respiratory symptoms that is 
beyond normal day-to-day variations and leads to a change in 
medication.21,22 Patients with pneumonia were not excluded, 
and pneumonia was defined as an acute respiratory infection 
combined with an infiltrate of the lungs, which was visible on 
an X-ray of the chest. The infiltrate had to be non-pre-existent, 
nor reasonably caused by another cause than pneumonia. 
 Further, patients had to be able to produce a sputum sample.
The medical ethics committee of Medisch Specrtum 
Twente, Enschede, the Netherlands approved the COMIC 
study and the amendment for the current study, and all 
patients provided written informed consent for both the 
COMIC study itself and the amendment. All patients 
received usual care, which included oral corticosteroids and 
amoxicillin/clavulanic acid started on the day of admission. 
Amoxicillin/clavulanic acid was administered according 
to regular care, which was either orally (500/125 mg three 
or four times a day) or intravenously (1,000/200 mg four 
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times a day). Some patients received oral and intravenous 
 amoxicillin/clavulanic acid sequentially.
Outcome measures
On the first day of admission, C-reactive protein was mea-
sured in blood using the NyoCard® CRP Single Test (Clindia 
Diagnostics, Leusden, the Netherlands). On the third day of 
treatment with amoxicillin/clavulanic acid, sputum and serum 
samples were collected. Sample collection was performed on 
the third day of treatment because, theoretically, steady-state 
amoxicillin concentrations in both serum and sputum should 
be reached by then.23 Serum samples were stored at –80°C. 
Sputum samples were stored at –80°C after a culture was 
performed.
Before measuring amoxicillin concentrations and beta-
lactamase activity in sputum, sputum samples were thawed 
and homogenized using a MagNA lyser (3×60 seconds at 
6,500 rpm; Roche Diagnostics, Indianapolis, IN, USA). 
Lysing of cells during the homogenization process was 
confirmed by microscopy. After homogenization, vials were 
centrifuged at 10,000 g for 5 minutes to separate cell debris. 
Amoxicillin concentrations in serum and homogenized 
sputum samples were determined using a high-performance 
liquid chromatography/tandem mass spectrometry method.
For amoxicillin, an a priori cut-off level of 2 mg/L was 
defined as an adequate concentration in both serum and 
sputum. This value corresponds to the MIC
90
 for  amoxicillin/
clavulanic acid. The MIC
90
 used in this study is derived from 
local susceptibility tests from the Regional Laboratory of 
Public Health and is comparable with data published by the 
European Committee On Susceptibility Testing.24
Beta-lactamase activity was measured directly in 
homogenized sputum samples by measuring the turnover 
rate of nitrocefin (Calbiochem, San Diego, CA, USA). 
Nitrocefin is a beta-lactam with chromogenic properties; 
it changes color from yellow to red under the influence of 
beta-lactamase activity. Nitrocefin turnover was measured 
with spectrophotometry at λ=490 nm in a mixture of 50 µL 
of homogenized sputum and 50 µL of a 0.025% nitrocefin 
solution. Beta-lactamase activity was quantified by compar-
ing the measured activity with the activity of a beta-lactamase 
positive lysate from a H. influenzae culture. Beta-lactamase 
activity was calculated as a percentage of the activity of the 
H. influenzae lysate.
Statistical analysis
Continuous variables are expressed as the mean (standard 
deviation [SD]) or as the median (interquartile range [IQR]). 
 Categorical variables are displayed as numbers (percentages). 
The crude relationship between beta-lactamase activity and 
sputum amoxicillin concentrations (,MIC
90
 or $MIC
90
) was 
analyzed using the Mann–Whitney U test. To identify con-
founders in this relationship, first the association of a priori 
selected possible confounders with beta-lactamase activity 
was analyzed by Pearson correlation tests, independent 
samples t-tests, and analysis of variance for normally dis-
tributed (continuous/dichotomous/categorical) variables. For 
non-normally distributed variables, this was performed with, 
respectively, Spearman correlation tests, Mann–Whitney 
U tests, and Kruskal–Wallis tests. Variables associated with 
beta-lactamase activity with a significance of P,0.15 were 
tested for an association with sputum amoxicillin concentra-
tion (,MIC
90
 or $MIC
90
). For categorical variables, these 
associations were tested by chi-square tests or by Fisher’s 
Exact tests, and for continuous variables by independent 
samples t-tests or Mann–Whitney U tests. Variables that 
were also associated with sputum amoxicillin concentration 
with a significance of P,0.15 were considered as potential 
confounders in the relationship between beta-lactamase activ-
ity and sputum amoxicillin concentration and were entered 
in a multivariate logistic regression model. Subsequently, 
variables with the highest P-values were eliminated step 
by step, until the fit of the model decreased significantly, 
based on the –2 log likelihood. The statistical analyses were 
performed using Statistical Package for the Social Sciences 
version 15.0 software (SPSS Inc., Chicago, IL, USA).
Results
Between November 2009 and March 2010, 147 patients were 
screened for eligibility (Figure 1). Of the 30 patients included, 
23 provided a sufficient amount of sputum. Table 1 shows the 
demographic and clinical characteristics of these 23 patients. 
The organisms isolated in all patients were confirmed to be 
susceptible to amoxicillin.
The univariate analysis showed no difference in 
beta-lactamase activity between patients with a sputum 
amoxicillin concentration ,MIC
90
 and patients with a 
concentration $MIC
90
 with, respectively, a median beta-
lactamase activity of 0.35 (IQR 0.26–0.59) and 0.32 (IQR 
0.18–0.62; P=0.79). Also when individual data of beta-
 lactamase activity and sputum amoxicillin concentrations 
were plotted in a scatter diagram (Figure 2) no correlation 
could be observed (r=-0.06, P=0.80). In 18 of 23 sputum 
samples (78%), amoxicillin concentrations were below the 
MIC
90
. In six of those samples (26%), the amoxicillin concen-
tration was undetectable. Seven of 23 serum samples (30%) 
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Table 2 Potential confounders: association with beta-lactamase 
activity
Association with beta-lactamase 
activity
Median beta-lactamase  
activity (% of reference)  
(IQR)
P-value
Sex
 Male
 Female
0.34 (0.25–0.60)
0.36 (0.23–0.85)
0.86
Exacerbation with pneumonia
 No
 Yes
0.33 (0.27–0.46)
0.55 (0.18–0.69)
0.31
GOLD classification
 I
 II
 III
 IV
0.55 (0.48–0.55)
0.44 (0.27–0.61)
0.30 (0.12–0.50)
0.36 (0.24–0.67)
0.46
Route of administration
 Oral
 Intravenous
0.31 (0.18–0.48)
0.57 (0.33–0.67)
0.06
Concurrent use of other antibiotics
 No
 Yes
0.34 (0.24–0.59)
0.36 (0.28–0.59)
0.77
Clavulanic acid, daily dose (mg)
 375
 500
 800
0.28 (0.17–0.37)
0.48 (0.33–0.48)
0.57 (0.33–0.67)
0.08
Correlation with beta- 
lactamase activity  
(Spearman’s rho)
P-value
Age -0.05 0.81
Amoxicillin level  
in serum mg/L
0.22 0.30
CRP concentration  
at admission mg/L
-0.37 0.09
Abbreviations: CRP, C-reactive protein; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; IQR, interquartile range.
Table 1 Baseline patient demographic and clinical characteristics
Characteristic n=23
Age, years (SD) 71.0 (8.9)
Sex
 Male (%)
 Female (%)
17 (74%) 
6 (26%)
GOLD classification
 I (%)
 II (%)
 III (%)
 IV (%)
2 (9%) 
6 (26%) 
8 (35%) 
7 (30%)
Route of administration of amoxicillin/clavulanic acid
 Oral (%)
 Intravenous (%)
15 (65%) 
8 (35%)
Median daily dose of clavulanic acid, mg (IQR) 375 (375–800)
Median concentration of amoxicillin
 In serum, mg/L (IQR)
 In sputum, mg/L (IQR)
4.7 (0.72–6.35) 
0.6 (0.00–1.74)
Median beta-lactamase activity, as % of reference (IQR) 0.34 (0.26–0.58)
Median CRP concentration at admission, mg/L (IQR) 40 (25–152)
Patients with both exacerbation of COPD  
and pneumonia
11 (48%)
Simultaneous use of other antibiotics 5 (22%)
Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive 
protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IQR, 
interquartile range; SD, standard deviation.
23 patients analyzed
Not enough sputum (n=7)
30 patients gave informed consent
147 patients screened
117 patients did not fulfill inclusion and
exclusion criteria:
No antibiotics (n=45)
Other antibiotic then
amoxicillin/clavulanic acid (n=32)
Not able to provide sputum sample
(n=9)
Maintenance use of antibiotics
(n=7)
Not willing to participate (n=7)
Other (n=8)
≥1 other exclusion criterion (n=9)
•
•
•
•
•
•
•
Figure 1 Flowchart of study inclusion.
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Figure 2 Scatter diagram of amoxicillin sputum concentration and beta-lactamase 
activity.
had an amoxicillin concentration below the MIC
90
. All serum 
samples had detectable levels of amoxicillin.
Only route of administration, median daily clavulanic acid 
dose, and C-reactive protein concentration at admission were 
univariately associated with beta-lactamase activity (P,0.15; 
Table 2) and were tested for an association with sputum 
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amoxicillin concentration. All three were also significantly 
associated with sputum amoxicillin concentration ,MIC
90
 or 
$MIC
90
 (Table 3). Multivariate logistic regression analysis 
showed no significant relationship between beta-lactamase 
activity and sputum amoxicillin concentrations ,MIC
90
 ver-
sus $MIC
90
 (odds ratio 0.53 for a 0.1% increase in beta-lac-
tamase activity; 95% confidence interval 0.23–1.2; P=0.13). 
The likelihood of reaching a sputum concentration $MIC
90
 
was 80 times greater when amoxicillin/clavulanic acid was 
administered intravenously versus via the oral route (odds 
ratio 80.6; 95% confidence interval 1.6–4100; P=0.03).
Discussion
No difference in beta-lactamase activity was found between 
patients with an amoxicillin concentration in sputum ,MIC
90
 
and patients with a concentration $MIC
90
 when treated with 
amoxicillin/clavulanic acid. Although we found that 78% of 
the patients had a low sputum concentration of amoxicillin 
(,MIC
90
), beta-lactamase activity does not seem to be the 
reason for this observation.
Beta-lactamase activity could not explain the low num-
bers of patients with an adequate amoxicillin concentration 
in sputum, so it seems that there should be other host-related 
or drug-related factors that influence the penetration across 
the blood-bronchus and alveolar-capillary barriers.
The most important host-related factor is the integrity 
of the anatomical barriers which may be damaged by inflam-
mation and mechanical injury. In the presence of inflamma-
tion, the distribution of amoxicillin may be altered because 
of increased membrane permeability.25,26 As observed 
in this and our previous study a high level of C-reactive 
protein, a marker of systemic inflammation, was related to 
higher amoxicillin levels.17 C-reactive protein levels could 
therefore possibly be used as a marker to determine COPD 
patients in whom adequate concentrations could be reached. 
However, this does not solve the problem of low concentra-
tions in the majority of patients; this is a worrying feature, 
especially because our previous study showed that this is also 
associated with significantly worse clinical outcomes.17 This 
warrants further investigation into more optimal treatment 
in these patients.
Since beta-lactam antibiotics such as amoxicillin do not 
cross membranes readily,27 it might be interesting to look at 
other antibiotics for the treatment of AECOPD that have a 
better penetration in sputum.28 Also, the possibility of indi-
vidually tailored amoxicillin dosing could be investigated, 
since it has been shown that increased systemic dosing of 
amoxicillin is associated with increased levels in sputum. 
We observed that intravenous administration was associated 
with a higher probability of reaching a sputum amoxicillin 
concentration $MIC
90
 and led to higher serum concentrations 
(data not shown), but still 50% of patients had a concentration 
,MIC
90
. Further, due to the wide confidence interval that was 
observed with this probability and since we did not observe 
any differences in the numbers of patients who reached the 
MIC
90
 between intravenous and oral administration in our 
earlier study,17 we cannot recommend a preference for use 
of either intravenous or oral administration to reach adequate 
amoxicillin sputum levels.
Alternative routes of administration such as inhalation of 
antibiotics could be considered. Aerosolized antibiotics have 
been proven to deliver high concentrations of antibiotics into 
the airways with low systemic bioavailability. Stockley et al 
treated patients with bronchiectasis with nebulized amoxicil-
lin and observed significant reductions in sputum purulence 
and volume after failure with the same drug given orally.29 
It would therefore be interesting to administer amoxicillin/
clavulanic acid via inhalation to reach the MIC
90
, and per-
haps to improve the efficacy of antibiotic treatment, as seen 
in cystic fibrosis.29,30
The observed concentration of amoxicillin in serum is in 
the range of concentrations found in earlier published studies, 
which showed concentrations between 3.87 and 45.2 mg/L. 
Observed concentrations of amoxicillin in sputum ranged 
between 0.23 and 4.4 mg/L.31–36 However, these concentra-
tions were measured in non-COPD patients and in healthy 
subjects.
Our study could have been influenced by selection bias, 
since we only included patients who were able to produce a 
sufficient amount of sputum on day 3. There might have been 
Table 3 Potential confounders: association with ,MIC90 or 
$MIC90
Association with ,MIC90 or $MIC90 
in sputum (n=23)
,MIC90  
in sputum
$MIC90  
in sputum
P-value
Route of administration
 Oral, n (%) 14 (93) 1 (7) 0.03
 Intravenous, n (%) 4 (50) 4 (50)
Median daily clavulanic  
acid dose, mg (IQR)
375 (375–575) 800 (589–800) 0.04
Median CRP concentration  
at admission, mg/L (IQR)
38 (21–57) 197 (56–206) 0.06
Abbreviations: CRP, C-reactive protein; IQR, interquartile range; MIC, minimum 
inhibitory concentration.
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a difference in beta-lactamase activity and/or  amoxicillin 
concentration between patients who were able to produce 
sputum and those who were not. Patients who were able to 
produce sputum may have had other characteristics in terms 
of presence/absence of bacteria or cause of exacerbation (eg, 
viral/bacterial infection). To overcome this issue, induction 
of sputum with hypertonic saline and the effects on possible 
dilution of amoxicillin concentration could be explored. 
Sputum induction has proven to be safe even during exacer-
bations in COPD patients.37
Since the majority of patients had an amoxicillin concen-
tration ,MIC
90
, the beta-lactamaseactivity of these patients 
could be compared to the beta-lactamaseactivity of only a 
small group of patiets with a concentration $MIC
90
. Although 
there seems to be no difference in median beta- lactamase 
activity, this study cannot definitely conclude that no relation-
ship exists, and further studies are still necessary.
Conclusion
We observed no relationship between beta-lactamase activity 
and sputum amoxicillin concentration (,MIC
90
 or $MIC
90
) 
in patients treated with amoxicillin/clavulanic acid for an 
acute exacerbation in COPD. More studies are necessary to 
confirm this finding. Further, we repeatedly observed that 
the majority of patients had low sputum concentrations of 
amoxicillin (,MIC
90
), suggesting that current treatment with 
antibiotics should be optimized.
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